While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. Sales ...

Vanguards VEA and VEU exchange trade funds both offer investors exposure to international markets and companies outside of ...

Novo Nordisk A/S Surges After Impressive Earnings Report ...

Highlights,Dow and,S&P 500,advanced during a broad market rally.,Alphabet and Disney experienced declines amid mixed earnings ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...

The nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) study was conducted to examine the effects of semaglutide ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill. While popular drugs like Ozempic and Wegovy are ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Wegovy: sales of weight loss injection more than double - The company said more than 45 million people were now ‘benefitting ...